A Clinical Research of Siddha Medicine in the treatment of Sooli Kanam (Childhood Asthma)

A Clinical Evaluation of Thulasi Ennai a Siddha Drug in the treatment of Soolikanam (Childhood Asthma) in Children.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/05/008540

Enrollment

Registered

2017-05-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Soolikanam (Childhood Asthma)

Interventions

Intervention1: Thulasi Ennai (Internal): 5ml of Thulasi Ennai administered orally OD dose at morning for a period of 40 days. Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age : 7 â?? 12 years 2. Cough 3. Wheezing 4. Tightness of chest 5. Shortness of breath 6. Abdominal bloating 7. Loss of appetite

Exclusion criteria

Exclusion criteria: 1. Children below 7 years and above 12 years 2. Haemoptysis 3. Pneumonia 4. Congenital heart disease 5. Status Asthmaticus

Design outcomes

Primary

Measure	Time frame
Efficacy of the trail drug is measured by Peak Expiratory Flow MeterTimepoint: Before treatment (0th day) and After treatment (40th day)	—

Secondary

Measure	Time frame
Secondary outcome is assessed by comparing the following parameters before and after the treatment 1.Improve clinical symptoms 2.Reduction in AEC and ESRTimepoint: Before treatment and After treatment	—

Countries

India

Contacts

Public ContactDr M Meenakshisundaram

National Institute of Siddha

mmssiddha@gmail.com9444214582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026